SecBot SecBot

SABSW

SAB Biotherapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001833214 Biotech & Drug Discovery
Former ticker of SAB Biotherapeutics, Inc. · SABS stock page →
—
Market cap
$391.2K
Nano cap
1 year
+1.7%
from $3.02 · Oct 28
30 days
−4.5%
from $3.21
52-week range
$2.49–4.59
−33% from high · low Oct 14
Avg volume 20D
674.3K
shares / day
Short interest
1.3K
≈0.0% of shares · +78.0%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BULLISH 2 reports · latest
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest BULLISH SAB Biotherapeutics presented positive Phase 1 clinical data for its SAB-142 therapy in Type 1 Diabetes…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 0 trimmed or exited.

  • Short sellersBUILDING

    Short interest +78.0% to 1.3K shares. 1.0 days to cover, ≈0.0% of shares.

  • TrendDOWNTREND

    7% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGADD6,567$85.00
WOLVERINE ASSET MANAGEMENT LLCADD3,289$42.00
UBS Group AGTRIM4,186$105.00
UBS Group AGTRIM6,186$192.00
BANK OF AMERICA CORP /DE/TRIM100$3.00
Walleye Trading LLCTRIM11,436$268.00
WOLVERINE ASSET MANAGEMENT LLCTRIM1,811$42.00
WOLVERINE ASSET MANAGEMENT LLCTRIM4,620$161.00

Quarterly 13F filings are due 45 days after each quarter ends.

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$71.4K
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 Listing status
Delisted: SABSW — removed from the Nasdaq symbol directory
SAB Biotherapeutics, Inc. - Warrant
Jun 30, 2026 Inst.
UBS Group AG — ADD
6,567 shares ($85.00)
Jun 30, 2026 Inst.
WOLVERINE ASSET MANAGEMENT LLC — ADD
3,289 shares ($42.00)
May 4, 2026 SEC
SAB Biotherapeutics entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for…
8-K — Impact 3/10
Apr 22, 2026 SEC
SAB Biotherapeutics presented positive Phase 1 clinical data for its SAB-142 therapy in Type 1 Diabetes patients…
8-K — Impact 6/10

Short side

FINRA· Oct 15, 2026
1,344
shares short
+78.0%
vs prior settlement
1.0
days to cover
≈0.0%
of shares outstanding
Trading halts
Oct 22, 2026DeletionResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 23, 2026
Listing
Delisted: SABSW — removed from the Nasdaq symbol directory
SAB Biotherapeutics, Inc. - Warrant
Oct 23, 2026
Trading halt
Halt Resumed: SABSW — trading resumed after D (Security Deletion)
Halted 2026-10-22T20:00:10.000Z | Resumed 2026-10-23T04:00:01.000Z
Oct 22, 2026
Trading halt
Trading Halt: SABSW — T12 (Additional Information Requested)
SAB Biotherapeutics Wt | Market: NASDAQ | Code: T12 — Additional Information Requested
Oct 22, 2026
Trading halt
Trading Halt: SABSW — D (Security Deletion)
SAB Biotherapeutics Wt | Market: NASDAQ | Code: D — Security Deletion
Oct 13, 2026
FDA
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes MIAMI, Oct. 13…

SecBot reports

2 filings · 1 bullish · 0 bearish · 1 neutral
All SABSW filing & press-release reports (2)